Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.50    1.50 (2.14%)
Bid:
71.00
Ask:
72.00
Spread: 1.00 (1.408%)
Market Cap: £325.40m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

3 Sep 2007 07:00

Avacta Group plc

Development Contract with the MOD's Defence science and technology laboratory

Field Detection of Liquid Chemicals

Avacta Group plc ("Avacta"), which develops detection and analysis technology aimed at the defence & security, pharmaceutical and clinical diagnostics markets, announces a contract with the Defence science and technology laboratory (Dstl), which is part of the UK Ministry of Defence.

Avacta is developing methods of analysing liquids using laser spectroscopy. The goal is to enable the rapid detection of liquids in the field.

Professor Alastair Smith, Chief Executive, Avacta, commented:

"We are delighted with the new contract for the development of a robust, prototype device. Laser detection and diagnostic devices are a key part of Avacta's portfolio of technologies and this contract with the MOD is an important step for the company."

3 September 2007Enquiries:Avacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk W.H. Ireland Ltd Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7099 1942 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes. A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

AVACTA GROUP PLC
Date   Source Headline
19th Jul 20163:13 pmRNSHolding(s) in Company
19th Jul 20167:15 amRNSHardman report: New Affimer opportunities
14th Jul 20167:00 amRNSCollaboration with Glythera
8th Jul 20167:00 amRNSDirector/PDMR Shareholding
22nd Jun 20167:00 amRNSAffimer Binders for Zika Virus Diagnostics
16th Jun 201611:08 amRNSIssue of Equity
13th Jun 20167:00 amRNSCollaboration with Mologic
29th Apr 20163:04 pmRNSDirector's Dealing
25th Apr 20167:00 amRNSHalf-year Report
19th Apr 20167:00 amRNSAffimer Therapeutic Platform Development Milestone
7th Apr 20167:00 amRNSDirector's Dealing
5th Apr 20167:00 amRNSInvestor Evening
15th Mar 20167:00 amRNSIssue of Equity
7th Mar 20167:00 amRNSAvacta Establishes Scientific Advisory Board
25th Feb 20164:34 pmRNSHolding(s) in Company
24th Feb 20167:00 amRNSGrant Funding Awarded
23rd Feb 201610:54 amRNSHardman & Co Issues Research Report
23rd Feb 20167:00 amRNSDirector's Dealing
17th Feb 20167:00 amRNSDirectors' Dealings and Issue of Equity
26th Jan 20168:05 amRNSShare Consolidation
25th Jan 20163:35 pmRNSResult of Annual General Meeting
25th Jan 20167:01 amRNSPre-close trading update
25th Jan 20167:00 amRNSPhilippe Cotrel Appointed Chief Commercial Officer
21st Jan 20167:00 amRNSProposed Shareholder Consolidation
7th Jan 20167:00 amRNSPosting of Annual Report & Accounts and AGM Notice
5th Jan 20167:00 amRNSIssue of Equity
10th Dec 20157:00 amRNSAppointment of Tony Gardiner as CFO
1st Dec 20154:44 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSIssue of Equity
23rd Nov 20157:00 amRNSIssue of Equity
6th Nov 201510:56 amRNSHolding(s) in Company
30th Oct 20157:00 amRNSIssue of Equity
26th Oct 20157:00 amRNSFinal Results
19th Oct 20157:00 amRNSAffimers improve disease resistance in plants
9th Oct 20157:00 amRNSRobust performance of Affimers on Luminex platform
8th Oct 20157:00 amRNSNotice of Results
17th Sep 20157:00 amRNSAppoints Dr Mike Owen as Non-executive Director
10th Sep 20157:00 amRNSTotal Voting Rights
3rd Sep 20157:00 amRNSIssue of Equity
5th Aug 201510:00 amRNSHolding(s) in Company
5th Aug 20157:00 amRNSHolding(s) in Company
4th Aug 201510:18 amRNSIssue of Equity
31st Jul 201510:42 amRNSResult of General Meeting
23rd Jul 20157:00 amRNSIssue of Equity
15th Jul 20157:00 amRNSConditional Placing to Raise up to £22.0 Million
7th Jul 20158:00 amRNSBoard Change
7th Jul 20157:00 amRNSPre-Close Trading Update
20th May 201511:48 amRNSHolding(s) in Company
19th May 201512:42 pmRNSHolding(s) in Company
11th May 20157:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.